<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01512225</url>
  </required_header>
  <id_info>
    <org_study_id>232-2011</org_study_id>
    <nct_id>NCT01512225</nct_id>
  </id_info>
  <brief_title>Enhancing Breast Milk Production With Domperidone in Mothers of Preterm Neonates</brief_title>
  <acronym>EMPOWER</acronym>
  <official_title>Enhancing Breast Milk Production With Domperidone in Mothers of Preterm Neonates</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunnybrook Health Sciences Centre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of Domperidone in those
      mothers who are identified as having difficulty with breast milk production to meet the
      nutritional needs of their infant in the neonatal intensive are unit hospitalization setting,
      and to determine how it should be considered in the care of mothers and their preterm infants
      without causing undesirable effects to either the mother or infant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is widely acknowledged that recent perinatal and neonatal technological advances (eg.
      assisted ventilation, surfactant, antenatal corticosteroids) have greatly enhanced the
      survival rate of very low birth weight and extremely low birth weight infants. A compelling
      body of evidence now exists to suggest that use of breast milk to feed preterm infants during
      initial hospitalization positively impacts their neurodevelopment during early childhood and
      beyond. In order to provide breastmilk, mothers of preterm infants have to begin to produce
      and mechanically express milk. However, these mothers are often faced with challenges in
      maintaining an adequate volume that will meet their infants' nutritional needs, as well as
      declines in production after several weeks despite a myriad of measures designed to assist in
      production. The primary hypothesis for this study is that Domperidone, through its
      pharmacologic action on increasing prolactin levels, will assist mothers experiencing
      inadequate breast milk production in increasing breast milk volumes to a level identified as
      being sufficient for continued pumping in the hospitalization period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increase in Breast Milk Production</measure>
    <time_frame>Day 0 to day 14</time_frame>
    <description>The primary outcome is the difference in the proportion of women having a 50% increase in breast milk volume at the end of 14 days of treatment with domperidone compared to mothers receiving placebo (mean day 14 volume minus mean day 0 volume at entry).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Increase in Breast Milk Volume on Day 28</measure>
    <time_frame>day 0 to day 28</time_frame>
    <description>Number of mothers who achieved 50% increase in milk volume on day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Breast Milk Volumes on Day 14</measure>
    <time_frame>Day 0 and day 14</time_frame>
    <description>Mean milk volumes between the two groups at 14 days of study intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Breast Milk Volumes on Day 28</measure>
    <time_frame>day 0 and 28</time_frame>
    <description>Mean milk volumes between the two groups at 28 days of study intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Volume Change From Day 0 to Day 14</measure>
    <time_frame>days 0 and 14</time_frame>
    <description>change on the volume of milk from day 0 to day 14 between the two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Volume Change on the Volume of Milk From Day 15 to Day 28</measure>
    <time_frame>day 15 and day 28</time_frame>
    <description>change on the volume of milk from day 15 to day 28 between the two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Provision of Breast Milk at Term Gestation</measure>
    <time_frame>term gestation</time_frame>
    <description>provision of breast milk as the primary source of nutrition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Provision of Breast Milk at 6 Weeks Post Term Gestation</measure>
    <time_frame>6 weeks post term gestation</time_frame>
    <description>Provision of breast milk at 6 weeks post term gestation as primary source of nutrition</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Low Milk Supply</condition>
  <arm_group>
    <arm_group_label>Domperidone for days 1 to 28</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Domperidone maleate tablets 10 mg orally three times daily from days 1 to 28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for days 1 to 14 and domperidone for day 15-28</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Identical placebo tablets 10 mg orally three times daily from days 1 to 14 followed by Domperidone maleate tablets 10 mg orally three times daily from days 15 to 28</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Domperidone maleate</intervention_name>
    <description>domperidone maleate tablet 10 mg orally three times daily for 28 days</description>
    <arm_group_label>Domperidone for days 1 to 28</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Tablet</intervention_name>
    <description>placebo tablet 10 mg orally three times daily for 14 days</description>
    <arm_group_label>Placebo for days 1 to 14 and domperidone for day 15-28</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Domperidone maleate</intervention_name>
    <description>domperidone maleate tablet 10 mg orally three times daily for 14 days</description>
    <arm_group_label>Placebo for days 1 to 14 and domperidone for day 15-28</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  mothers of a preterm infant born &lt; 30 completed weeks gestation (23 0/7-29 6/7 weeks)

          -  postpartum period of 7-21 days

          -  mechanically pumping a minimum average of 6 times a day in the 4-7 days prior to
             enrollment

          -  experiencing inadequate milk supply defined as providing &lt; 100% of the average of the
             daily nutritional intake during the previous 72-hour period prior to enrollment based
             on a fluid intake of 250 mL/kg/d or experiencing a clinical reduction of approximately
             20% from a peak volume during the previous 72-hour period prior to enrollment

        Exclusion Criteria:

          -  history of known or suspected cardiac dysrhythmias (tachyarrhythmia, Q-Tc
             prolongation) or currently on an anti-arrhythmic medication

          -  currently experiencing mastitis

          -  previous breast surgery, including augmentation or reduction, nipple piercing and/or
             the use of nipple rings/studs within the last year, or any reduction

          -  known chronic or debilitating illness, known abnormal liver function or gastric
             abnormalities gastrointestinal that will be exacerbated by the use of a prokinetic,
             examples include hemorrhage or blockage, actively treated with acid reflux which
             requires treatment for greater than 5 days and includes H2 blockers (occasional use of
             H2 blockers for heartburn or mild acid reflux is not considered an exclusion) and HIV

          -  known to have a prolactin-releasing pituitary tumor

          -  receiving medications known to alter the metabolism and pharmacokinetics of
             domperidone (eg. oral &quot;azole&quot; antifungals, erythromycin antibiotics, monoamine oxidase
             inhibitors (MAO) inhibitors) or medications that have dopaminergic or antidopaminergic
             activity or affect prolactin levels

          -  mothers of higher order pregnancies (triplet, or more)

          -  currently smoking 6 or more cigarette per day as reported by the mother
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth V Asztalos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marsha Campbell-Yeo, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IWK Health Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Orlando Da Silva, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital London Health Sciences Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>Asztalos EV, Campbell-Yeo M, da Silva OP, Ito S, Kiss A, Knoppert D; EMPOWER Study Collaborative Group. Enhancing Human Milk Production With Domperidone in Mothers of Preterm Infants. J Hum Lact. 2017 Feb;33(1):181-187. doi: 10.1177/0890334416680176. Epub 2017 Jan 20.</citation>
    <PMID>28107101</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2012</study_first_submitted>
  <study_first_submitted_qc>January 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2012</study_first_posted>
  <results_first_submitted>November 7, 2016</results_first_submitted>
  <results_first_submitted_qc>March 8, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 20, 2017</results_first_posted>
  <last_update_submitted>March 8, 2017</last_update_submitted>
  <last_update_submitted_qc>March 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breastmilk</keyword>
  <keyword>domperidone</keyword>
  <keyword>preterm</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Maleic acid</mesh_term>
    <mesh_term>Domperidone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment took place from June 1, 2012 to June 30, 2015 in 8 Neonatal Intensive Care Units in Canada</recruitment_details>
      <pre_assignment_details>Mothers could be identified in the NICU as early as day 4 until day 18 post-delivery. Additional counseling and support by the lactation consultant with respect to non-pharmacologic techniques were offered. If there was no response to the techniques, the mother was considered eligible for the trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group A: Domperidone</title>
          <description>Domperidone 10 mg orally three times daily for 28 days
Domperidone maleate: domperidone 10 mg orally three times daily for 28 days</description>
        </group>
        <group group_id="P2">
          <title>Group B: Placebo + Domperidone</title>
          <description>Identical placebo 10 mg orally three times daily for 14 days followed by domperidone 10 mg orally three times daily for 14 days
Domperidone maleate plus placebo: identical placebo 10 mg orally three times daily for 14 days followed by domperidone 10 mg orally three times daily for 14 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Provided Day 14 Volume</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group A: Domperidone</title>
          <description>Domperidone 10 mg orally three times daily for 28 days
Domperidone maleate: domperidone 10 mg orally three times daily for 28 days</description>
        </group>
        <group group_id="B2">
          <title>Group B: Placebo + Domperidone</title>
          <description>Identical placebo 10 mg orally three times daily for 14 days followed by domperidone 10 mg orally three times daily for 14 days
Domperidone maleate plus placebo: identical placebo 10 mg orally three times daily for 14 days followed by domperidone 10 mg orally three times daily for 14 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="45"/>
            <count group_id="B2" value="45"/>
            <count group_id="B3" value="90"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.25" lower_limit="20.96" upper_limit="40.59"/>
                    <measurement group_id="B2" value="33.56" lower_limit="23.23" upper_limit="39.50"/>
                    <measurement group_id="B3" value="32.41" lower_limit="20.96" upper_limit="40.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="90"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Ethnicity was self-declared</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Caucasian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Aboriginal</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Parity</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>0</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;/= 1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Type of pregnancy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Singleton</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Twins</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean milk Volume at entry</title>
          <units>millilitres</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="121" spread="96"/>
                    <measurement group_id="B2" value="115" spread="95"/>
                    <measurement group_id="B3" value="118" spread="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Increase in Breast Milk Production</title>
        <description>The primary outcome is the difference in the proportion of women having a 50% increase in breast milk volume at the end of 14 days of treatment with domperidone compared to mothers receiving placebo (mean day 14 volume minus mean day 0 volume at entry).</description>
        <time_frame>Day 0 to day 14</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A: Domperidone</title>
            <description>Domperidone 10 mg orally three times daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Group B: Placebo + Domperidone</title>
            <description>Identical placebo 10 mg orally three times daily for 14 days followed by domperidone 10 mg orally three times daily for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Increase in Breast Milk Production</title>
          <description>The primary outcome is the difference in the proportion of women having a 50% increase in breast milk volume at the end of 14 days of treatment with domperidone compared to mothers receiving placebo (mean day 14 volume minus mean day 0 volume at entry).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Increase in Breast Milk Volume on Day 28</title>
        <description>Number of mothers who achieved 50% increase in milk volume on day 28</description>
        <time_frame>day 0 to day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A: Domperidone</title>
            <description>Domperidone 10 mg orally three times daily for 28 days
Domperidone maleate: domperidone 10 mg orally three times daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Group B: Placebo + Domperidone</title>
            <description>Identical placebo 10 mg orally three times daily for 14 days followed by domperidone 10 mg orally three times daily for 14 days
Domperidone maleate plus placebo: identical placebo 10 mg orally three times daily for 14 days followed by domperidone 10 mg orally three times daily for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Increase in Breast Milk Volume on Day 28</title>
          <description>Number of mothers who achieved 50% increase in milk volume on day 28</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Breast Milk Volumes on Day 14</title>
        <description>Mean milk volumes between the two groups at 14 days of study intervention</description>
        <time_frame>Day 0 and day 14</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A: Domperidone</title>
            <description>Domperidone 10 mg orally three times daily for 28 days
Domperidone maleate: domperidone 10 mg orally three times daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Group B: Placebo + Domperidone</title>
            <description>Identical placebo 10 mg orally three times daily for 14 days followed by domperidone 10 mg orally three times daily for 14 days
Domperidone maleate plus placebo: identical placebo 10 mg orally three times daily for 14 days followed by domperidone 10 mg orally three times daily for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Breast Milk Volumes on Day 14</title>
          <description>Mean milk volumes between the two groups at 14 days of study intervention</description>
          <units>millilitres</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="267" spread="189"/>
                    <measurement group_id="O2" value="217" spread="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Breast Milk Volumes on Day 28</title>
        <description>Mean milk volumes between the two groups at 28 days of study intervention</description>
        <time_frame>day 0 and 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A: Domperidone</title>
            <description>Domperidone 10 mg orally three times daily for 28 days
Domperidone maleate: domperidone 10 mg orally three times daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Group B: Placebo + Domperidone</title>
            <description>Identical placebo 10 mg orally three times daily for 14 days followed by domperidone 10 mg orally three times daily for 14 days
Domperidone maleate plus placebo: identical placebo 10 mg orally three times daily for 14 days followed by domperidone 10 mg orally three times daily for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Breast Milk Volumes on Day 28</title>
          <description>Mean milk volumes between the two groups at 28 days of study intervention</description>
          <units>millilitres</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="290" spread="211"/>
                    <measurement group_id="O2" value="302" spread="230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Volume Change From Day 0 to Day 14</title>
        <description>change on the volume of milk from day 0 to day 14 between the two groups</description>
        <time_frame>days 0 and 14</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A: Domperidone</title>
            <description>Domperidone 10 mg orally three times daily for 28 days
Domperidone maleate: domperidone 10 mg orally three times daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Group B: Placebo + Domperidone</title>
            <description>Identical placebo 10 mg orally three times daily for 14 days followed by domperidone 10 mg orally three times daily for 14 days
Domperidone maleate plus placebo: identical placebo 10 mg orally three times daily for 14 days followed by domperidone 10 mg orally three times daily for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Volume Change From Day 0 to Day 14</title>
          <description>change on the volume of milk from day 0 to day 14 between the two groups</description>
          <units>millilitres</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="254" lower_limit="-100" upper_limit="2129"/>
                    <measurement group_id="O2" value="175" lower_limit="-100" upper_limit="923"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Volume Change on the Volume of Milk From Day 15 to Day 28</title>
        <description>change on the volume of milk from day 15 to day 28 between the two groups</description>
        <time_frame>day 15 and day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A: Domperidone</title>
            <description>Domperidone 10 mg orally three times daily for 28 days
Domperidone maleate: domperidone 10 mg orally three times daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Group B: Placebo + Domperidone</title>
            <description>Identical placebo 10 mg orally three times daily for 14 days followed by domperidone 10 mg orally three times daily for 14 days
Domperidone maleate plus placebo: identical placebo 10 mg orally three times daily for 14 days followed by domperidone 10 mg orally three times daily for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Volume Change on the Volume of Milk From Day 15 to Day 28</title>
          <description>change on the volume of milk from day 15 to day 28 between the two groups</description>
          <units>millilitres</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22" lower_limit="-68" upper_limit="200"/>
                    <measurement group_id="O2" value="49" lower_limit="-100" upper_limit="254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Provision of Breast Milk at Term Gestation</title>
        <description>provision of breast milk as the primary source of nutrition</description>
        <time_frame>term gestation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A: Domperidone</title>
            <description>Domperidone 10 mg orally three times daily for 28 days
Domperidone maleate: domperidone 10 mg orally three times daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Group B: Placebo + Domperidone</title>
            <description>Identical placebo 10 mg orally three times daily for 14 days followed by domperidone 10 mg orally three times daily for 14 days
Domperidone maleate plus placebo: identical placebo 10 mg orally three times daily for 14 days followed by domperidone 10 mg orally three times daily for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Provision of Breast Milk at Term Gestation</title>
          <description>provision of breast milk as the primary source of nutrition</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Provision of Breast Milk at 6 Weeks Post Term Gestation</title>
        <description>Provision of breast milk at 6 weeks post term gestation as primary source of nutrition</description>
        <time_frame>6 weeks post term gestation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A: Domperidone</title>
            <description>Domperidone 10 mg orally three times daily for 28 days
Domperidone maleate: domperidone 10 mg orally three times daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Group B: Placebo + Domperidone</title>
            <description>Identical placebo 10 mg orally three times daily for 14 days followed by domperidone 10 mg orally three times daily for 14 days
Domperidone maleate plus placebo: identical placebo 10 mg orally three times daily for 14 days followed by domperidone 10 mg orally three times daily for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Provision of Breast Milk at 6 Weeks Post Term Gestation</title>
          <description>Provision of breast milk at 6 weeks post term gestation as primary source of nutrition</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Group A: Domperidone</title>
          <description>Domperidone 10 mg orally three times daily for 28 days
Domperidone maleate: domperidone 10 mg orally three times daily for 28 days</description>
        </group>
        <group group_id="E2">
          <title>Group B: Placebo + Domperidone</title>
          <description>Identical placebo 10 mg orally three times daily for 14 days followed by domperidone 10 mg orally three times daily for 14 days
Domperidone maleate plus placebo: identical placebo 10 mg orally three times daily for 14 days followed by domperidone 10 mg orally three times daily for 14 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedRa</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="31" subjects_affected="10" subjects_at_risk="45"/>
                <counts group_id="E2" events="23" subjects_affected="3" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Elizabeth Asztalos</name_or_title>
      <organization>Sunnybrook Research Institute</organization>
      <phone>416-480-6100, ext 87791</phone>
      <email>elizabeth.asztalos@sunnybrook.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

